Search

STAT-ON™ is an objective tool that registers ON-OFF fluctuations making possible to know the state of the patient at every moment of the day in normal life. Our aim was to analyze the opinion of different Parkinson's disease experts about the STAT-ON™ tool after using the device in a real clinical practice setting (RCPS).

The complete set of MX2 and MX4 (M = C, Si, Ge, Sn, Pb and X = F, Cl, Br, I) group 14 halides are studied with density functional theory and quasirelativistic effective core potentials. To analyze the role of density inhomogeneities and the asymptotic behavior of the Kohn−Sham effective potential in these molecules, the following exchange-correlation energy functionals are tested:  local, semilocal (generalized gradient), and hybrid functionals. For comparison, Hartree−Fock results are also presented. Fully optimized geometries are in very good agreement with experimentally available data and with other high-level theoretical calculations. The energy differences associated with the dissociation and disproportionation reactions are reported. Zero-point corrections and atomic spin−orbit effects are included in these reaction energies. The dissociation energies predicted at the Hartree−Fock level are underestimated, the local energy differences are overestimated, and both the semilocal and hybrid approaches provide the best estimates for these reaction energies. The disproportionation energies, which are commonly used to explore the relative stability of different atomic valences, show a behavior that departs from that commonly known for reactions involving a single atom:  the local and semilocal disproportionation energies have very similar values and follow the same trends.

Introduction. In a degenerative disorder such as Parkinson’s disease (PD), it is important to establish clinical stages that allow to know the course of the disease. Our aim was to analyze whether a scale combining Hoehn and Yahr’s motor stage (H&Y) and the nonmotor symptoms burden (NMSB) (assessed by the nonmotor symptoms scale (NMSS)) provides information about the disability and the patient’s quality of life (QoL) with regard to a defined clinical stage. Materials and Methods. Cross-sectional study in which 603 PD patients from the COPPADIS cohort were classified according to H&Y (1, stage I; 2, stage II; 3, stage III; 4, stage IV/V) and NMSB (A: NMSS = 0–20; B: NMSS = 21–40; C: NMSS = 41–70; D: NMSS ≥ 71) in 16 stages (HY.NMSB, from 1A to 4D). QoL was assessed with the PDQ-39SI, PQ-10, and EUROHIS-QOL8 and disability with the Schwab&England ADL (Activities of Daily Living) scale. Results. A worse QoL and greater disability were observed at a higher stage of H&Y and NMSB (p<0.0001). Combining both (HY.NMSB), patients in stages 1C and 1D and 2C and 2D had significantly worse QoL and/or less autonomy for ADL than those in stages 2A and 2B and 3A and 3B, respectively (p<0.005; e.g., PDQ-39SI in 1D [n = 15] vs 2A [n = 101]: 28.6 ± 17.1 vs 7.9 ± 5.8; p<0.0001). Conclusion. The HY.NMSB scale is simple and reflects the degree of patient involvement more accurately than the H&Y. Patients with a lower H&Y stage may be more affected if they have a greater NMS burden.